Preclinical studies have shown statins’ direct antiproliferative and immunomodulatory effects, promoting immunogenic cell death in KRAS (Kirsten rat sarcoma viral oncogene homolog)—mutated cancer cells, through increased expression of “eat me” signals and damage-associated molecular patterns, while reducing proteins that suppress T cell antitumor responses [205]. This evidence concerns the gene KRAS and cancer.